Serum level of salusin β as an indicator of metabolic disorders in Acute Lymphoblastic Leucaemia and Wilms Tumour survivors

Background Cardiovascular diseases (CVD) are one of long-term side effects of the childhood cancers treatment. Salusin β is an indicator of developing atherosclerosis. Aim To assess the prevalence of established risk factors for CVD and the assessment of new indicator for CVD risk - salusin β in long-term acute lymphoblastic leukemia (ALLs) and Wilms tumour (WTs) survivors. Methods 37 ALLs and 11 WTs at least 5 years after the end of oncological treatment undergone physical examination and laboratory tests after an overnight fast. Laboratory tests included lipid profile, serum level of glucose, renal parameters and salusin β. Results The both groups didn’t vary in age, time from the end of the treatment, number of obese persons, BP, lipid profile, serum creatinine and glucose level. ALLs had higher weight and greater waist circumference. Serum cystatin was higher and cystatin-based eGFR lower among WTs. Salusin β was higher in group WTs, but the result was not statistically significant. Conclusions ALLs and WTs differ in types of long-term side effects. ALLs present rather metabolic problems, WTs - lower eGFR. Salusin β seems to implicate development of hypertension rather than metabolic disorders like obesity. Further investigations are necessary to confirm this statement.